Nath Bio-Genes (India) Limited announced its unaudited standalone and consolidated financial results for the quarter ended December 31, 2025, during a board meeting on January 31, 2026. On a standalone basis, the company reported a significant 78.89% year-on-year (YoY) increase in revenue from operations, reaching ₹65.96 Crores. Standalone Profit After Tax (PAT) surged by 172.35% YoY to ₹7.23 Crores, aided by a jump in other income and exceptional items. However, the consolidated performance showed a divergence; while revenue grew at a similar pace of 78.88% YoY to ₹65.96 Crores, consolidated PAT declined by 39.45% YoY to ₹1.60 Crores. Sequentially, compared to Q2 FY26, standalone revenue rose by 43.46% while standalone profit grew by 72.14%. On a consolidated basis, revenue increased by 50.41% quarter-on-quarter (QoQ), but profit dropped by 66.80%.

Nath Bio-Genes (India) Limited is a leading Indian agri-tech company specializing in the research, production, and marketing of hybrid seeds, including cotton, paddy, maize, and various vegetable crops. The company has a strong focus on research and development, maintaining a robust pipeline of products designed to improve crop yields and withstand disease and pest pressures. In recent 2025 updates, the company noted that its Rabi crop portfolio, specifically wheat, mustard, and vegetables like tomatoes and chilies, is well-positioned to benefit from favorable sectoral tailwinds such as increased Minimum Support Prices (MSP). Furthermore, Nath Bio-Genes has expanded its international footprint, particularly in Uzbekistan, where its joint venture successfully cultivated cotton seeds on over 600 hectares. The company remains zero-debt and has recently undergone a management transition with Mr. Amol Gupta taking over as CFO. Notable institutional and trust investors include the Bakulesh Shah Private Trust and Arati Farms Private Limited.